ArticleWorld journal of surgical oncology2023

Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.

Lu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.